Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)
Go back to Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 14.88 -0.42 (2.75%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.30 | 52 Week High | $117.12 | |||
| Open | $15.10 | 52 Week Low | $46.52 | |||
| Day High | $15.25 | P/E | N/A | |||
| Day Low | $14.63 | EPS | $-1.97 | |||
| Volume | 5,926,146 | |||||
